% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • supermba_2000 supermba_2000 Nov 28, 2012 11:11 PM Flag

    Canaccord Genuity Reiterates Buy on Avanir as Drug Sales Ramp

    November 28, 2012 2:23 PM EST

    Canaccord Genuity maintained a Buy on Avanir Pharmaceuticals with a price target of $6.00 after the company reported drug sales that beat estimates. Nuedexta gross sales came in a $15.4 million, beating consensus views of $14.8 million.

    Commenting on the developments, analysts Ritu Baral said, "Recent sales trends continue to appear steady, and we foresee continued sales ramp in 2013."

    Canaccord Genuity's $6 target on Avanir Pharmaceuticals is based on a sum-of- the-parts analysis.

    Sentiment: Strong Buy